Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 10/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21452520 | 0.79 | MTNR1A (0.37) | ACACBMTNR1AMTNR1BALDH1A1ALOX15 | |
| SCHEMBL21452634 | 0.76 | TRPV1 (0.37) | ACACBMTNR1AMTNR1BALDH1A1ALOX15 | |
| SCHEMBL17560257 | 0.72 | KDM4E (0.46) | ACACBMTNR1AMTNR1BALDH1A1TSHR | |
| SCHEMBL13452337 | 0.72 | KISS1R (0.41) | ACACBMTNR1AMTNR1BALDH1A1ALOX15 | |
| SCHEMBL23992087 | 0.69 | ACACB (0.40) | ACACBMTNR1AMTNR1BALDH1A1 | |
| SCHEMBL18531990 | 0.69 | MTNR1A (0.42) | ACACBMTNR1AMTNR1BALDH1A1ALOX15 | |
| SCHEMBL21452443 | 0.68 | ACACB (0.36) | ACACBMTNR1AMTNR1BALDH1A1 | |
| SCHEMBL24520557 | 0.68 | ACACB (0.38) | ACACBMTNR1AMTNR1BALDH1A1CYP2D6 | |
| SCHEMBL18520329 | 0.68 | — | — | |
| SCHEMBL8435514 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200246480-A1 | ANTI-CD22 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246480-A1 | ANTI-CD22 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF | CD22, CD2, CD2BP2 | ACACB 4367/4885MTNR1A 1611/4885MTNR1B 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.